Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
DiaMedica Therapeutics receives FDA clearance for DM199 IND application » 08:56
05/17/21
05/17
08:56
05/17/21
08:56
DMAC

DiaMedica Therapeutics

$6.52 /

+0.03 (+0.46%)

DiaMedica Therapeutics…

DiaMedica Therapeutics announced that the FDA has accepted the company's investigational new drug, or IND, application. The company plans to proceed with a pivotal Phase 2/3 study of DM199 for the treatment of patients with Acute Ischemic Stroke, or AIS.

ShowHide Related Items >><<
DMAC DiaMedica Therapeutics
$6.52 /

+0.03 (+0.46%)

DMAC DiaMedica Therapeutics
$6.52 /

+0.03 (+0.46%)

04/08/21 Oppenheimer
DiaMedica Therapeutics initiated with an Outperform at Oppenheimer
03/17/21 Guggenheim
Guggenheim likes DiaMedica into kidney disease data, ups target to $25
03/12/21 Craig-Hallum
DiaMedica Therapeutics price target raised to $20 from $15 at Craig-Hallum
02/17/21 Roth Capital
DiaMedica Therapeutics initiated with a Buy at Roth Capital
DMAC DiaMedica Therapeutics
$6.52 /

+0.03 (+0.46%)

DMAC DiaMedica Therapeutics
$6.52 /

+0.03 (+0.46%)

Over a month ago
Conference/Events
DiaMedica Therapeutics management to meet virtually with B.Riley » 04:55
05/11/21
05/11
04:55
05/11/21
04:55
DMAC

DiaMedica Therapeutics

$7.91 /

-0.64 (-7.49%)

Virtual Meeting to be…

Virtual Meeting to be held on May 11 hosted by B. Riley.

ShowHide Related Items >><<
DMAC DiaMedica Therapeutics
$7.91 /

-0.64 (-7.49%)

DMAC DiaMedica Therapeutics
$7.91 /

-0.64 (-7.49%)

04/08/21 Oppenheimer
DiaMedica Therapeutics initiated with an Outperform at Oppenheimer
03/17/21 Guggenheim
Guggenheim likes DiaMedica into kidney disease data, ups target to $25
03/12/21 Craig-Hallum
DiaMedica Therapeutics price target raised to $20 from $15 at Craig-Hallum
02/17/21 Roth Capital
DiaMedica Therapeutics initiated with a Buy at Roth Capital
DMAC DiaMedica Therapeutics
$7.91 /

-0.64 (-7.49%)

DMAC DiaMedica Therapeutics
$7.91 /

-0.64 (-7.49%)

Conference/Events
DiaMedica Therapeutics management to meet virtually with Oppenheimer » 05:55
05/07/21
05/07
05:55
05/07/21
05:55
DMAC

DiaMedica Therapeutics

$8.59 /

-0.85 (-9.00%)

Virtual Meeting to be…

Virtual Meeting to be held on May 7 hosted by Oppenheimer.

ShowHide Related Items >><<
DMAC DiaMedica Therapeutics
$8.59 /

-0.85 (-9.00%)

DMAC DiaMedica Therapeutics
$8.59 /

-0.85 (-9.00%)

04/08/21 Oppenheimer
DiaMedica Therapeutics initiated with an Outperform at Oppenheimer
03/17/21 Guggenheim
Guggenheim likes DiaMedica into kidney disease data, ups target to $25
03/12/21 Craig-Hallum
DiaMedica Therapeutics price target raised to $20 from $15 at Craig-Hallum
02/17/21 Roth Capital
DiaMedica Therapeutics initiated with a Buy at Roth Capital
DMAC DiaMedica Therapeutics
$8.59 /

-0.85 (-9.00%)

DMAC DiaMedica Therapeutics
$8.59 /

-0.85 (-9.00%)

Conference/Events
DiaMedica Therapeutics management to meet virtually with B.Riley » 08:59
05/06/21
05/06
08:59
05/06/21
08:59
DMAC

DiaMedica Therapeutics

$9.45 /

+0.005 (+0.05%)

Virtual Meeting to be…

Virtual Meeting to be held on May 11 hosted by B. Riley.

ShowHide Related Items >><<
DMAC DiaMedica Therapeutics
$9.45 /

+0.005 (+0.05%)

DMAC DiaMedica Therapeutics
$9.45 /

+0.005 (+0.05%)

04/08/21 Oppenheimer
DiaMedica Therapeutics initiated with an Outperform at Oppenheimer
03/17/21 Guggenheim
Guggenheim likes DiaMedica into kidney disease data, ups target to $25
03/12/21 Craig-Hallum
DiaMedica Therapeutics price target raised to $20 from $15 at Craig-Hallum
02/17/21 Roth Capital
DiaMedica Therapeutics initiated with a Buy at Roth Capital
DMAC DiaMedica Therapeutics
$9.45 /

+0.005 (+0.05%)

DMAC DiaMedica Therapeutics
$9.45 /

+0.005 (+0.05%)

Conference/Events
DiaMedica Therapeutics management to meet virtually with Oppenheimer » 10:30
05/04/21
05/04
10:30
05/04/21
10:30
DMAC

DiaMedica Therapeutics

$9.23 /

-0.21 (-2.22%)

Virtual Meeting to be…

Virtual Meeting to be held on May 7 hosted by Oppenheimer.

ShowHide Related Items >><<
DMAC DiaMedica Therapeutics
$9.23 /

-0.21 (-2.22%)

DMAC DiaMedica Therapeutics
$9.23 /

-0.21 (-2.22%)

04/08/21 Oppenheimer
DiaMedica Therapeutics initiated with an Outperform at Oppenheimer
03/17/21 Guggenheim
Guggenheim likes DiaMedica into kidney disease data, ups target to $25
03/12/21 Craig-Hallum
DiaMedica Therapeutics price target raised to $20 from $15 at Craig-Hallum
02/17/21 Roth Capital
DiaMedica Therapeutics initiated with a Buy at Roth Capital
DMAC DiaMedica Therapeutics
$9.23 /

-0.21 (-2.22%)

DMAC DiaMedica Therapeutics
$9.23 /

-0.21 (-2.22%)

Initiation
DiaMedica Therapeutics initiated with an Outperform at Oppenheimer » 16:07
04/08/21
04/08
16:07
04/08/21
16:07
DMAC

DiaMedica Therapeutics

$9.30 /

-0.06 (-0.64%)

Oppenheimer analyst…

Oppenheimer analyst Francois Brisebois initiated coverage of DiaMedica Therapeutics with an Outperform rating and $27 price target. The company is developing DM199 for the treatment of acute ischemic stroke and various types of chronic kidney diseases, noted Brisebois, who views the drug's mechanism of action as "scientifically strong." He believes the recent Type B response from the FDA reinforces the value of the company's Phase 2 data and he views the upcoming IgAN data as "relatively de-risked and potentially differentiated," the analyst tells investors.

ShowHide Related Items >><<
DMAC DiaMedica Therapeutics
$9.30 /

-0.06 (-0.64%)

DMAC DiaMedica Therapeutics
$9.30 /

-0.06 (-0.64%)

03/17/21 Guggenheim
Guggenheim likes DiaMedica into kidney disease data, ups target to $25
03/12/21 Craig-Hallum
DiaMedica Therapeutics price target raised to $20 from $15 at Craig-Hallum
02/17/21 Roth Capital
DiaMedica Therapeutics initiated with a Buy at Roth Capital
01/04/21 Lake Street
DiaMedica Therapeutics price target raised to $28 from $14 at Lake Street
DMAC DiaMedica Therapeutics
$9.30 /

-0.06 (-0.64%)

DMAC DiaMedica Therapeutics
$9.30 /

-0.06 (-0.64%)

Conference/Events
DiaMedica Therapeutics to hold a conference call » 11:25
03/19/21
03/19
11:25
03/19/21
11:25
DMAC

DiaMedica Therapeutics

$9.59 /

+0.11 (+1.16%)

Management, along with…

Management, along with Key Opinion Leaders (KOLs) Scott Kasner, MD and Paolo Madeddu, MD, discuss DM19 for treatment of Acute Ischemic Stroke on a conference call to be held on March 19 at 12 pm. Webcast Link

ShowHide Related Items >><<
DMAC DiaMedica Therapeutics
$9.59 /

+0.11 (+1.16%)

DMAC DiaMedica Therapeutics
$9.59 /

+0.11 (+1.16%)

03/17/21 Guggenheim
Guggenheim likes DiaMedica into kidney disease data, ups target to $25
03/12/21 Craig-Hallum
DiaMedica Therapeutics price target raised to $20 from $15 at Craig-Hallum
02/17/21 Roth Capital
DiaMedica Therapeutics initiated with a Buy at Roth Capital
01/04/21 Lake Street
DiaMedica Therapeutics price target raised to $28 from $14 at Lake Street
DMAC DiaMedica Therapeutics
$9.59 /

+0.11 (+1.16%)

DMAC DiaMedica Therapeutics
$9.59 /

+0.11 (+1.16%)

Conference/Events
DiaMedica Therapeutics to hold a conference call » 09:29
03/19/21
03/19
09:29
03/19/21
09:29
DMAC

DiaMedica Therapeutics

$9.63 /

-0.52 (-5.12%)

Management, along with…

Management, along with Key Opinion Leaders (KOLs) Scott Kasner, MD and Paolo Madeddu, MD, discuss DM19 for treatment of Acute Ischemic Stroke on a conference call to be held on March 19 at 12 pm. Webcast Link

ShowHide Related Items >><<
DMAC DiaMedica Therapeutics
$9.63 /

-0.52 (-5.12%)

DMAC DiaMedica Therapeutics
$9.63 /

-0.52 (-5.12%)

03/17/21 Guggenheim
Guggenheim likes DiaMedica into kidney disease data, ups target to $25
03/12/21 Craig-Hallum
DiaMedica Therapeutics price target raised to $20 from $15 at Craig-Hallum
02/17/21 Roth Capital
DiaMedica Therapeutics initiated with a Buy at Roth Capital
01/04/21 Lake Street
DiaMedica Therapeutics price target raised to $28 from $14 at Lake Street
DMAC DiaMedica Therapeutics
$9.63 /

-0.52 (-5.12%)

DMAC DiaMedica Therapeutics
$9.63 /

-0.52 (-5.12%)

Recommendations
Guggenheim likes DiaMedica into kidney disease data, ups target to $25 » 11:32
03/17/21
03/17
11:32
03/17/21
11:32
DMAC

DiaMedica Therapeutics

$9.45 /

-0.17 (-1.77%)

Guggenheim analyst Etzer…

Guggenheim analyst Etzer Darout raised the firm's price target on DiaMedica Therapeutics to $25 from $16 and keeps a Buy rating on the shares ahead of the new drug submission of the Phase 2/3 stroke study later this month and Q2 topline readout in diabetic kidney disease for DM199. Low KLK1 levels are associated with greater risk of kidney disease as well as stroke, and clinical evidence from KLK1 studies in Asia and early clinical data from DM199 suggest that restoration of KLK1 to normal levels has the potential to address the unmet need in both indications, says the analyst. Darout likes DiaMedica's risk/reward heading into the diabetic kidney disease data and reiterates the stock as a top pick.

ShowHide Related Items >><<
DMAC DiaMedica Therapeutics
$9.45 /

-0.17 (-1.77%)

DMAC DiaMedica Therapeutics
$9.45 /

-0.17 (-1.77%)

03/12/21 Craig-Hallum
DiaMedica Therapeutics price target raised to $20 from $15 at Craig-Hallum
02/17/21 Roth Capital
DiaMedica Therapeutics initiated with a Buy at Roth Capital
01/04/21 Lake Street
DiaMedica Therapeutics price target raised to $28 from $14 at Lake Street
10/30/20 Guggenheim
DiaMedica Therapeutics initiated with a Buy at Guggenheim
DMAC DiaMedica Therapeutics
$9.45 /

-0.17 (-1.77%)

DMAC DiaMedica Therapeutics
$9.45 /

-0.17 (-1.77%)

Over a quarter ago
Recommendations
DiaMedica Therapeutics price target raised to $20 from $15 at Craig-Hallum » 08:46
03/12/21
03/12
08:46
03/12/21
08:46
DMAC

DiaMedica Therapeutics

$9.14 /

+0.28 (+3.16%)

Craig-Hallum analyst…

Craig-Hallum analyst Alexander Nowak raised the firm's price target on DiaMedica Therapeutics to $20 from $15 and keeps a Buy rating on the shares. All value-adding events remain on track setting up a 2021 packed with catalysts including data readouts from all three phase 2 kidney cohorts, IND and fast-track stroke submissions later this month and stroke pivotal starting this summer, Nowak tells investors in a research note. The analyst believes successful phase 2 data is worth at least $250M and with stroke moving to pivotal and kidney on the way, he thinks a minimum $500M valuation is within reach.

ShowHide Related Items >><<
DMAC DiaMedica Therapeutics
$9.14 /

+0.28 (+3.16%)

DMAC DiaMedica Therapeutics
$9.14 /

+0.28 (+3.16%)

02/17/21 Roth Capital
DiaMedica Therapeutics initiated with a Buy at Roth Capital
01/04/21 Lake Street
DiaMedica Therapeutics price target raised to $28 from $14 at Lake Street
10/30/20 Guggenheim
DiaMedica Therapeutics initiated with a Buy at Guggenheim
07/08/20 Maxim
DiaMedica Therapeutics initiated with a Buy at Maxim
DMAC DiaMedica Therapeutics
$9.14 /

+0.28 (+3.16%)

DMAC DiaMedica Therapeutics
$9.14 /

+0.28 (+3.16%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.